STEAP2 SIR-T

STEAP2 SIR-T is a preclinical-stage cell therapy being developed by Angeles Therapeutics for the treatment of prostate cancer and potentially other solid tumors. The therapy utilizes the company's proprietary Synthetic Immune Receptor (SIR-T) platform, which engineers T-cells to express a synthetic receptor designed to mimic the natural T-cell receptor (TCR) signaling complex. This approach is intended to provide more regulated and physiological T-cell activation compared to traditional Chimeric Antigen Receptor (CAR) T-cells, potentially improving efficacy and safety in the immunosuppressive microenvironment of solid tumors. The specific target, Six-Transmembrane Epithelial Antigen of the Prostate 2 (STEAP2), is a cell surface protein significantly overexpressed in prostate cancer cells while showing limited expression in normal tissues.

Other names

Angeles Therapeutics STEAP2 cell therapyAngeles Therapeutics-STEAP2-cell therapy-SIR-T